Diabetes, obesity & metabolism · 2025
A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Riveline Jean-Pierre, Julla Jean-Baptiste, Bonnemaison Elisabeth, Joubert Michael, Lablanche Sandrine, Gazagnes Agnès Sola, Demarsy Delphine, Gouet Didier, Schaepelynck Pauline, Amouyal Chloé, Vale Fabienne Dalla, Schletzer-Mari Anne, Clavel Sylvaine, Spiteri Anne, Campinos Catherine, Favre Sandrine, Tauveron Igor, Mathivon Laurence, Borot Sophie, Fagherazzi Guy, Breton Marc D, Gautier Jean-François, Renard Eric, OB2F study group
Аннотация
AIMS: A nationwide observational study was conducted to assess the 12-month effectiveness of AID systems in the routine care of people with Type 1 diabetes (PwT1D).
METHODS: All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and % PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9-10 mmol/L) after 1 year with AID.
RESULTS: A total of 2741 PwT1D were included: 44.4% male, age 38 years [29], BMI 24.5 kg/m2 [6.7], diabetes duration 19 years [20]. AID systems were MiniMed 780G in 49.7%, Tandem Control-IQ in 49.3%, others in 1%. After 12 months, TIR increased from 58.0 [21] to 70.1% [14] while HbA1c levels decreased from 7.6 [1.2] to 7.0% [0.8]. Percent PwT1D experiencing severe hypoglycaemia (SH) decreased from 4.1 to 0.9%, and ketoacidosis from 1.2 to 0.6%. All improvements were observed after 3 months, sustained through 12 months, and statistically significant (p < 0.05). Only 2.8% of PwT1D discontinued AID.
CONCLUSIONS: Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.
METHODS: All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and % PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9-10 mmol/L) after 1 year with AID.
RESULTS: A total of 2741 PwT1D were included: 44.4% male, age 38 years [29], BMI 24.5 kg/m2 [6.7], diabetes duration 19 years [20]. AID systems were MiniMed 780G in 49.7%, Tandem Control-IQ in 49.3%, others in 1%. After 12 months, TIR increased from 58.0 [21] to 70.1% [14] while HbA1c levels decreased from 7.6 [1.2] to 7.0% [0.8]. Percent PwT1D experiencing severe hypoglycaemia (SH) decreased from 4.1 to 0.9%, and ketoacidosis from 1.2 to 0.6%. All improvements were observed after 3 months, sustained through 12 months, and statistically significant (p < 0.05). Only 2.8% of PwT1D discontinued AID.
CONCLUSIONS: Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.